PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Real-World data sought on leukemia drug ponatinib
Disease control Not yet recruitingThis study reviews medical records of about 103 adults with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) who received ponatinib as their first treatment in routine care. Researchers want to see how many patients achieve a deep level of cancer control (complete mol…
Matched conditions: PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated May 26, 2026 08:59 UTC
-
Promising new combo targets Hard-to-Treat leukemia in kids and young adults
Disease control Not yet recruitingThis study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), for children, teens, and young adults up to age 30 who have a certain type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal…
Matched conditions: PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 19, 2026 12:01 UTC